<DOC>
	<DOC>NCT01349283</DOC>
	<brief_summary>The primary purpose of this study is to determine whether HepavaxGene TF is non-inferior to the comparator vaccine both at impeding hepatitis B transmission from mothers positive for chronic hepatitis B (Stratum 1) to their children and also in terms of seroconversion rate in children of mothers negative for chronic hepatitis B (Stratum 2) one month after completion of the immunization schedule.</brief_summary>
	<brief_title>Immunogenicity and Safety of the Hepatitis B Vaccine Hepavax-Gene TF and a Comparator Hepatitis B Vaccine in Newborns</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Three types of subject: Neonates whose mothers are positive for both HBsAg and HBeAg Neonates whose mothers are positive for only HBsAg Neonates whose mothers are negative for both HBsAg and HBeAg INCLUSION CRITERIA: Fullterm neonates with gestational age from 37 weeks to 42 weeks; Apgar scores are no less than 7 at birth; Neonates with standard body temperature (auxiliary temperature &lt; 37.1°); Neonates weighing ≥ 2,500 grams at birth; Neonates with icteric index within the normal range (physiologic jaundice is permitted); Informed consent form signed by parent/guardian; The requirements of the clinical trial protocol can be observed on the basis of the opinion of the investigator. EXCLUSION CRITERIA: Subject's parent has a history of family diseases such as convulsion and brain diseases; Mothers have low immunologic function or a history of organ transplantation or hemodialysis; Subject's parent is allergic to any composition of Hepatitis B vaccine; A family history of thrombocytopenia, or other disturbance of blood coagulation, which may result in a contraindication for intramuscular injection; Known immunologic function damage; Mothers had received gamma globulin or immunoglobulin injection during pregnancy; Any congenital malformation Known or suspected to suffer from diseases such as active infection and cardiovascular disease; Any condition believed by the investigator to have possible impact on trial evaluation.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Day</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Hepatitis B Vaccine</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Antigen</keyword>
	<keyword>Antibody</keyword>
	<keyword>Vaccination</keyword>
</DOC>